Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Biomacromolecules ; 24(10): 4478-4493, 2023 10 09.
Artigo em Inglês | MEDLINE | ID: mdl-36757736

RESUMO

This study is about multiple responsiveness in biomedical materials. This typically implies "orthogonality" (i.e., one response does not affect the other) or synergy (i.e., one increases efficacy or selectivity of the other), but an antagonist effect between responses may also occur. Here, we describe a family of very well-defined amphiphilic and micelle-forming block copolymers, which show both oxidative and temperature responses. They are produced via successive anionic ring-opening polymerization of episulfides and RAFT polymerization of dialkylacrylamides and differ only in the ratio between inert (N,N-dimethylacrylamide, DMA) and temperature-sensitive (N,N-diethylacrylamide, DEA) units. By scavenging Reactive Oxygen Species (ROS), these polymers are anti-inflammatory; through temperature responsiveness, they can macroscopically aggregate, which may allow them to form depots upon injection. The localization of the anti-inflammatory action is an example of synergy. An extensive evaluation of toxicity and anti-inflammatory effects on in vitro models, including BV2 microglia, C8D30 astrocytes and primary neurons, shows a link between capacity of aggregation and detrimental effects on viability which, albeit mild, can hinder the anti-inflammatory potential (antagonist action). Although limited in breadth (e.g., only in vitro models and only DEA as a temperature-responsive unit), this study suggests that single-responsive controls should be used to allow for a precise assessment of the (synergic or antagonist) potential of double-responsive systems.


Assuntos
Doenças Neuroinflamatórias , Polímeros , Humanos , Micelas , Espécies Reativas de Oxigênio , Anti-Inflamatórios , Polimerização
2.
J Am Chem Soc ; 144(46): 21304-21317, 2022 11 23.
Artigo em Inglês | MEDLINE | ID: mdl-36367536

RESUMO

This study addresses well-known shortcomings of poly(ethylene glycol) (PEG)-based conjugates. PEGylation is by far the most common method employed to overcome immunogenicity and suboptimal pharmacokinetics of, for example, therapeutic proteins but has significant drawbacks. First, PEG offers no protection from denaturation during lyophilization, storage, or oxidation (e.g., by biological oxidants, reactive oxygen species); second, PEG's inherent immunogenicity, leading to hypersensitivity and accelerated blood clearance (ABC), is a growing concern. We have here developed an 'active-stealth' polymer, poly(thioglycidyl glycerol)(PTGG), which in human plasma is less immunogenic than PEG (35% less complement activation) and features a reactive oxygen species-scavenging and anti-inflammatory action (∼50% less TNF-α in LPS-stimulated macrophages at only 0.1 mg/mL). PTGG was conjugated to proteins via a one-pot process; molar mass- and grafting density-matched PTGG-lysozyme conjugates were superior to their PEG analogues in terms of enzyme activity and stability against freeze-drying or oxidation; the latter is due to sacrificial oxidation of methionine-mimetic PTGG chains. Both in mice and rats, PTGG-ovalbumin displayed circulation half-lives up to twice as long as PEG-ovalbumin, but most importantly─and differently from PEG─without any associated ABC effect seen either in the time dependency of blood concentration, in the liver/splenic accumulation, or in antipolymer IgM/IgG titers. Furthermore, similar pharmacokinetic results were obtained with PTGGylated/PEGylated liposomal nanocarriers. PTGG's 'active-stealth' character therefore makes it a highly promising alternative to PEG for conjugation to biologics or nanocarriers.


Assuntos
Polietilenoglicóis , Polímeros , Ratos , Camundongos , Humanos , Animais , Polietilenoglicóis/metabolismo , Polímeros/farmacologia , Glicerol , Espécies Reativas de Oxigênio , Ovalbumina , Estabilidade Proteica
3.
Biomacromolecules ; 21(2): 305-318, 2020 02 10.
Artigo em Inglês | MEDLINE | ID: mdl-31793790

RESUMO

We show the first example of a synergic approach of oxidant (ROS) scavenging carrier and ROS-responsive drug release in the context of a potential therapy against osteoporosis, aiming to inhibit the differentiation of inflammatory cells into osteoclasts. In our "tandem" approach, a branched amphiphilic, PEGylated polysulfide (PPSES-PEG) was preferred over a linear analogue, because of improved homogeneity in the aggregates (spherical micelles vs mixture of wormlike and spherical), increased stability, and higher drug loading (up to ∼22 wt % of antiosteoclastic rapamycin). These effects are ascribed to the branching inhibiting crystallization in the polysulfide blocks. The ROS-scavenging micelles alone were already able to reduce osteoclastogenesis in a RAW 264.7 model, but the "drug" combination (the polymer itself + rapamycin released only under oxidation) completely abrogated the process. An important take-home message is that the synergic performance depended very strongly on the oxidant:oxidizable group molar ratio, a parameter to carefully tune in the perspective of targeting specific diseases.


Assuntos
Portadores de Fármacos/química , Micelas , Nanomedicina/métodos , Osteogênese/efeitos dos fármacos , Sirolimo/farmacocinética , Animais , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacologia , Antioxidantes/química , Antioxidantes/farmacologia , Portadores de Fármacos/farmacocinética , Liberação Controlada de Fármacos , Camundongos , Osteoclastos/efeitos dos fármacos , Osteogênese/fisiologia , Oxirredução , Células RAW 264.7 , Espécies Reativas de Oxigênio/metabolismo , Sulfetos/química , Sulfetos/farmacologia
4.
Macromol Rapid Commun ; 40(1): e1800699, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30474897

RESUMO

In this review, a general introduction to biological oxidants (focusing on reactive oxygen species, ROS) and the biomedical rationale behind the development of materials capable of responding to ROS is provided. The state of the art for preparative aspects and mechanistic responses of the most commonly used macromolecular ROS-responsive systems, including polysulfides, polyselenides, polythioketals, polyoxalates, and also oligoproline- and catechol-based materials, is subsequently given. The endowment of multiple responsiveness, with specific emphasis on the cases where a molecular logic gate behavior can be obtained, is focused on. Finally, fundamental open issues, which include implications of the "drug"-like character of ROS-responsive materials (inherent anti-inflammatory behavior) and the poor quantitative understanding of ROS roles in biology, are discussed.


Assuntos
Polímeros/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Substâncias Macromoleculares/química , Substâncias Macromoleculares/metabolismo , Estrutura Molecular , Oxirredução , Polímeros/química
5.
Int J Mol Sci ; 20(18)2019 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-31533205

RESUMO

We present the evaluation of a sulfoxide-based polymer (poly(propylene sulfoxide), PPSO) as a potential 'stealth' macromolecule, and at the same time as a pharmacologically active (anti-inflammatory/anti-oxidant) material. The combination of these two concepts may at first seem peculiar since the gold standard polymer in biomaterials and drug delivery, poly(ethylene glycol) (PEG), is 'stealth' due to its chemical and biological inertness, which makes it hardly biologically active. Polysulfoxides, on the contrary, may couple a substantial inertness towards biomolecules under homeostatic conditions, with the possibility to scavenge reactive oxygen species (ROS) associated to inflammation. Polysulfoxides, therefore, are rather uniquely, 'active' 'stealth' polymers. Here, we describe the synthesis of PPSO through controlled oxidation of poly(propylene sulfide) (PPS), which on its turn was obtained via anionic ring-opening polymerization. In vitro, PPSO was characterized by a low toxicity (IC50 ~7 mg/mL at 24 h on human dermal fibroblasts) and a level of complement activation (in human plasma) and macrophage uptake slightly lower than PEG of a similar size. Importantly, and differently from PEG, on LPS-activated macrophages, PPSO showed a strong and dose-dependent ROS (hydrogen peroxide and hypochlorite)-scavenging activity, which resulted in a corresponding reduction of cytokine production.


Assuntos
Anti-Inflamatórios/farmacologia , Antioxidantes/farmacologia , Biopolímeros/farmacologia , Sulfóxidos/farmacologia , Animais , Anti-Inflamatórios/química , Antioxidantes/química , Biopolímeros/química , Sobrevivência Celular/efeitos dos fármacos , Fenômenos Químicos , Fibroblastos , Humanos , Camundongos , Estrutura Molecular , Peso Molecular , Polimerização , Células RAW 264.7 , Espécies Reativas de Oxigênio/metabolismo , Sulfóxidos/química
6.
Biomater Adv ; 153: 213537, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37406516

RESUMO

This paper is about the effects of reactive oxygen species (ROS) - and of their nanoparticle-mediated extracellular removal - in the TGF-ß1-induced differentiation of fibroblasts (human dermal fibroblasts - HDFa) to more contractile myofibroblasts, and in the maintenance of this phenotype. Here, poly(propylene sulfide) (PPS) nanoparticles have been employed on 2D and 3D in vitro models, showing extremely low toxicity and undergoing negligible internalization, thereby ensuring an extracellular-only action. Firstly, PPS nanoparticles abrogated ROS-mediated downstream molecular events such as glutathione oxidation, NF-κB activation, and heme oxidase-1 (HMOX) overexpression. Secondly, PPS nanoparticles were also capable to inhibit, prevent and reverse the TGF-ß1-induced upregulation of key biomechanical elements, such as ED-a fibronectin (EF-A FN) and alpha-smooth muscle actin (α-SMA), respectively markers of protomyofibroblastic and of myofibroblastic differentiation. We also confirmed that ROS alone are ineffective promoters of the myofibroblastic transition, although their presence contributes to its stabilization. Finally, the particles also countered TGF-ß1-induced matrix- and tissue-level phenomena, e.g., the upregulation of collagen type 1, the development of aberrant collagen type 1/3 ratios and the contracture of HDFa 3D-seeded fibrin constructs. In short, experimental data at molecular, cellular and tissue levels show a significant potential in the use of PPS nanoparticles as anti-fibrotic agents.


Assuntos
Miofibroblastos , Fator de Crescimento Transformador beta1 , Humanos , Miofibroblastos/patologia , Fator de Crescimento Transformador beta1/farmacologia , Espécies Reativas de Oxigênio/farmacologia , Fibroblastos , Fibrose , Colágeno Tipo I/farmacologia
7.
Int J Pharm ; 416(1): 85-96, 2011 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-21704141

RESUMO

Five celecoxib (CXB) acylamide sodium salts, MP-CXB, Cy-CXB, Bz-CXB, CBz-CXB and FBz-CXB were synthesized and characterized. Two simple, fast and validated RP-HPLC methods were developed for simultaneous quantitative determination of the amides and celecoxib in aqueous and biological samples and LOD and LOQ were ≤13.6 and ≤40ng/mL, respectively. The solubility and logP(app) of the amides, in relevant media, were determined. The chemical hydrolysis, at 60, 70 and 80°C, of MP-CXB was studied at GIT-relevant pH (1.2, 6.8 and 7.4) and of CY-CXB was studied at skin relative pH (5.4 and 7.4). Significant hydrolysis was observed for MP-CXB at pH 1.2 only with half-lives 28.28, 11.64 and 3.53h at 60, 70 and 80°C, respectively, with extrapolated half-lives of 2060 and 443h at 25 and 37°C, respectively. The hydrolysis of all amides was studied in rat live homogenate and only Cy-CXB was hydrolyzed with half-life of 3.79h. The hydrolysis of MP-CXB and Cy-CXB was studied in human plasma and neither was hydrolyzed. It is finally suggested that hydrophobic interactions plays a role in the binding of susceptible acylamides to the hepatic hydrolyzing enzyme since only amides with saturated hydrocarbon chains underwent hydrolysis.


Assuntos
Amidas/síntese química , Amidas/farmacocinética , Desenho de Fármacos , Pirazóis/química , Pirazóis/farmacocinética , Sulfonamidas/química , Sulfonamidas/farmacocinética , Amidas/química , Animais , Celecoxib , Estabilidade de Medicamentos , Meia-Vida , Humanos , Concentração de Íons de Hidrogênio , Hidrólise , Interações Hidrofóbicas e Hidrofílicas , Fígado/metabolismo , Estrutura Molecular , Plasma/metabolismo , Ratos , Solubilidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA